Important legal notice
Contact   |   Search on Europa   

Infectious Diseases Graphic element print icon Graphic element
  Homepage
Graphic element General information
  RTD Infectious Diseases Unit
  Developing countries
  EDCTP
   
Graphic element Projects
  About FP6 Funding
  FP6 projects
  About FP5 Funding
  FP5 projects
   
   
Graphic element Addressed Diseases
  HIV/AIDS
- News
  Malaria
  Tuberculosis
   
Graphic element Calls for proposals
  FP7 Calls
   
Graphic element Contact corner
  Unit
  Scientific officers
  Subscribe to our mailing list
   
 
TARGETING NEF
HIV/AIDS
Framework programme: 5
Project number:
QLK2-CT-2000-01630
EC contribution: € 1 300 000
Duration: 36 months
Type: RS
Starting date: 1 September 2000
Graphic element The HIV-1 Pathogenicity Factor Nef as a Novel Therapeutic Target
Keywords: HIV; AIDS; Nef; structure-function analysis; assay development; high-throughput screening; drug discovery; antiviral agents

Summary:

The objective of this project is to extend the ongoing basic research in the laboratories of this consortium in order to transform the HIV-1 pathogenicity factor Nef into a therapeutic target that would be attractive and readily available to the pharmaceutical industry for exploitation in drug discovery.

Problem:

At the end of 2001, an estimated 40 million people globally were living with HIV. Although the number of new HIV-1 infections per year in EU countries has not recently decreased, the new combinations of anti-HIV drugs have reduced AIDS deaths significantly and improved the quality of life and capacity to contribute to society for many HIV-infected individuals in Europe. Despite these positive developments, however, it is painfully apparent that the current AIDS therapies are insufficient and problematic, and this situation is likely to get worse as multiresistant HIV strains become more common. Therefore, finding new drugs against the current molecular targets of anti-HIV therapies, as well as innovative new drugs that target novel HIV functions is critically needed.

HIV-1 Nef is a promising candidate for a novel therapeutic target in AIDS. Although Nef is not required for the replicative cycle of HIV, Nef is critical for the development of AIDS in HIV-infected individuals and SIV-infected rhesus monkeys. By enhancing HIV replication and protecting the infected cells from the immune system, Nef can contribute to the development of high viral loads, which is the driving force of HIV disease progression. In addition, Nef has an independent pathogenic function, and when expressed in transgenic mice in the absence of any other HIV components can cause a pathological condition that recapitulates many of the salient features of human AIDS. Therefore, drugs that target Nef might not only inhibit HIV replication, but could also have a completely new, and possibly highly beneficial, therapeutic effect through the inhibition of Nef-induced pathogenicity. Moreover, blocking the immune-evading effects of Nef, would also be anticipated to lead to a better immunological control of HIV infection, which is particularly noteworthy considering that, with the current therapies, eradication of HIV from a patient has to date remained a theoretical possibility. Despite this remarkable promise, Nef has so far not been widely exploited as a therapeutic target. This has been mainly because the molecular mechanisms by which Nef functions in the infected cell remain incompletely understood. Thus, Nef has been considered a difficult target for pharmaceutical exploitation.

Aim:

The first aim of this project is to develop a consensus regarding the biochemical and cellular functions of Nef and the molecular surfaces of Nef that are critical for mediating these functions. By using carefully standardised study systems and reagents, by examining multiple putative Nef functions in parallel, and by testing a large number of potentially relevant function-modifying mutations in the background of a single molecular clone of Nef, this project aims to resolve the current controversies regarding Nef function. We also aim to develop novel mouse models that could be used to test the pathogenic function of Nef and the ability of different mutations in Nef to abolish it in an in vivo setting. The most important aim of the project is to generate a set of user-friendly high-throughput assays that could be used by the pharmaceutical industry to screen for compounds that would block those Nef functions that were found to be most relevant for its pathogenic effect.

Expected results:

The expected results of this project will be:

  1. a functional map of HIV-1 Nef, from which it can be predicted which molecular determinants in Nef should be targeted by small molecular drugs in order to block the most relevant functions of Nef
  2. a set of new biochemical and cell-based high-throughput assays for use in industrial scale drug-discovery to find such pharmaceutical compounds 

Potential applications:

The results of this project are expected to be applicable to the discovery of novel anti-HIV drugs by the pharmaceutical industry. Because of the multifactorial role of Nef in AIDS pathogenesis explained above, such Nef inhibitors could be highly synergistic if combined with the drugs currently used to treat HIV infection that act by directly inhibiting viral enzymes involved in HIV replication.

Coordinator:

Kalle Saksela
University of Tampere, Institute of Medical Technology
33014 Tampere
Finland
Tel: +358 3 215 7029
Fax: +358 3 215 8597
E-mail: kalle.saksela@uta.fi
Website: http://www.uta.fi/imt

Partners:

Principal
Scientific
Participants
Official Address Other Information
2Andreas BaurUniversity of Erlangen
Dermatologische Klinik und Poliklinik
Hartmannstr. 14
DE-91052 Erlangen
Germany
Tel: +49 9131 853 6307
Fax: +49 9131 8532724
E-mail: Andreas.Baur@derma.med.uni-erlangen.de
Website: http://www.viro.med.uni-erlangen.de
3Mark HarrisUniversity of Leeds
Division of Microbiology
Thoresby Place
UK-LS2 9JT Leeds
United Kingdom
Tel: +44 113 343 5632
Fax: +44 113 343 5638
E-mail: mharris@bmb.leeds.ac.uk
Website: http://www.bmb.leeds.ac.uk/
4Hans-Georg KraeusslichUniversity of Heidelberg
Hygiene-Institut / Abt. Virologie
Im Neuenheimer Feld 324
DE-69120 Heidelbeg
Germany
Tel: +49 6221 565001
Fax: +49 6221 565003
E-mail: Hans-Georg_Kraeusslich@med.uni-heidelberg.de
Website: http://www.klinikum.uni-heidelberg.de/index.php?id=4722
5Olivier SchwartzInstitut Pasteur
Laboratoire Rétrovirus et Transfert Génétique
25 rue du Roux
FR-75724 Paris Cedex 15
France
Tel: +33 1 45 68 83 53
Fax: +33 1 45 68 89 40
E-mail: schwartz@pasteur.fr
Website: http://www.klinikum.uni-heidelberg.de/index.php?id=4722

 
 
top
Graphic element